We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

137 hedge funds and large institutions have $1.66B invested in Acceleron Pharma in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 49 increasing their positions, 41 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 41

13% more capital invested

Capital invested by funds: $1.47B → $1.66B (+$189M)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

8% less funds holding

Funds holding: 149 → 137 (-12)

17% less call options, than puts

Call options by funds: $4.12M | Put options by funds: $4.95M

39% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 28

Holders
137
Holders Change
-12
Holders Change %
-8.05%
% of All Funds
3.11%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.14%
New
17
Increased
49
Reduced
41
Closed
28
Calls
$4.12M
Puts
$4.95M
Net Calls
-$837K
Net Calls Change
+$8.23M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$51.7M
2
BlackRock
BlackRock
New York
+$16.3M
3
TCM
Tekla Capital Management
Massachusetts
+$8.39M
4
State Street
State Street
Massachusetts
+$8.27M
5
American Century Companies
American Century Companies
Missouri
+$6.8M

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$30.3M
2
Deutsche Bank
Deutsche Bank
Germany
-$14.7M
3
Millennium Management
Millennium Management
New York
-$13.4M
4
MWNA
Marshall Wace North America
New York
-$5.91M
5
IBT
International Biotechnology Trust
United Kingdom
-$5.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Lord, Abbett & Co
51
Lord, Abbett & Co
New Jersey
$3.44M -$74K -1,972 -2%
TA
52
Teachers Advisors
New York
$3.4M +$807K +21,508 +37%
CAM
53
Cormorant Asset Management
Massachusetts
$3.18M – – –
CS
54
Candriam SCA
Luxembourg
$3.1M -$1.69M -45,000 -38%
HLA
55
Hamilton Lane Advisors
Pennsylvania
$2.95M -$206K -5,487 -7%
AllianceBernstein
56
AllianceBernstein
Tennessee
$2.93M +$970K +25,850 +60%
PP
57
PDT Partners
New York
$2.73M +$3.26K +87 +0.1%
Swiss National Bank
58
Swiss National Bank
Switzerland
$2.64M – – –
TD Asset Management
59
TD Asset Management
Ontario, Canada
$2.61M – – –
MOACM
60
Mutual of America Capital Management
New York
$2.55M -$3.56K -95 -0.2%
California State Teachers Retirement System (CalSTRS)
61
California State Teachers Retirement System (CalSTRS)
California
$2.51M +$281K +7,499 +15%
Balyasny Asset Management
62
Balyasny Asset Management
Illinois
$2.48M +$2.19M +58,500 New
PIM
63
Platinum Investment Management
Australia
$2.48M – – –
BAMCO Inc
64
BAMCO Inc
New York
$2.29M +$326K +8,700 +19%
State of New Jersey Common Pension Fund D
65
State of New Jersey Common Pension Fund D
New Jersey
$2.25M – – –
Citigroup
66
Citigroup
New York
$2.19M -$30.3M -806,656 -94%
Bank of America
67
Bank of America
North Carolina
$2.17M -$1.74M -46,380 -48%
AA
68
ALPS Advisors
Colorado
$2.13M +$454K +12,098 +32%
OA
69
Omega Advisors
New York
$2.12M – – –
Two Sigma Investments
70
Two Sigma Investments
New York
$1.62M +$1.43M +38,121 New
CS
71
Credit Suisse
Switzerland
$1.61M -$1.96M -52,128 -58%
RhumbLine Advisers
72
RhumbLine Advisers
Massachusetts
$1.59M -$39.3K -1,048 -3%
Wells Fargo
73
Wells Fargo
California
$1.42M -$370K -9,878 -23%
EWM
74
Evercore Wealth Management
New York
$1.39M – – –
ProShare Advisors
75
ProShare Advisors
Maryland
$1.27M +$223K +5,952 +25%
1 2
3
4 5

XLRN Hedge Fund Activity: Q4 2017 in Review

137 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2017, worth a combined $1.66B — up 13% from $1.47B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of XLRN and 17 opened new positions — a net loss of 11 holders — while 41 trimmed existing stakes and 49 added.

The largest buyer was Fidelity Investments, adding an estimated $51.7M. The largest seller was Citigroup, cutting an estimated $30.3M.

  • 137 institutional investors held Acceleron Pharma (XLRN) as of Q4 2017, down from 149 in Q3 2017.
  • Funds reported $1.66B of Acceleron Pharma stock for Q4 2017, up 13% quarter-over-quarter.
  • 17 funds opened new Acceleron Pharma positions in Q4 2017 and 28 closed out, a net change of -11 holders.
  • The largest Acceleron Pharma buyer in Q4 2017 was Fidelity Investments, an estimated $51.7M added.
  • The largest Acceleron Pharma seller in Q4 2017 was Citigroup, an estimated $30.3M sold.

Based on aggregated 13F filings for Q4 2017.